Oxygen-independent methods, systems and devices for the enzymatic colorimetric assay and detection of biochemical analytes. Two systems are described, both of which produce less than one equivalent of dye per equivalent of substrate, maintaining dye concentrations in the range where Beer's law predicts a linear color-concentration relationship. One system produces an analog color signal from an analog analyte input, the other system produces a digital color signal from an analog analyte input. |
Citations|
| US3964871 | Dec 18, 1974 | Jun 22, 1976 | Becton, Dickinson and Company | Method and device for detecting glucose | | US4556634 | Jun 22, 1983 | Dec 3, 1985 | Toyo Jozo Kabushiki Kaisha | High sensitivity assay method | | US4629697 | Dec 23, 1983 | Dec 16, 1986 | Merck Patent Gesellschaft mit beschrankter Haftung | Test system and procedure for the determination of NAD (P) H | | US4761381 | Feb 26, 1987 | Aug 2, 1988 | Miles Inc. | Volume metering capillary gap device for applying a liquid sample onto a reactive surface |
Referenced by|
| US5278079 | Sep 2, 1992 | Jan 11, 1994 | Enzymatics, Inc. | Sealing device and method for inhibition of flow in capillary measuring devices | | US5439813 | Jun 3, 1994 | Aug 8, 1995 | E. I. Du Pont de Nemours and Company | Production of glyoxylic acid with glycolate oxidase and catalase immobilized on oxirane acrylic beads | | US5510245 | Jan 18, 1994 | Apr 23, 1996 | Bayer Corporation | Composition and method of assaying for ketone bodies | | US5518891 | Aug 25, 1993 | May 21, 1996 | Actimed Laboratories, Inc. | Dye forming composition and detection of hydrogen peroxide therewith | | US5523214 | May 9, 1994 | Jun 4, 1996 | Biotest Aktiengesellschaft | Method of visually demonstrating the presence of microorganisms, identifying them, and testing them for sensitivity to antibiotics with redox indicators | | US5550028 | Jun 7, 1995 | Aug 27, 1996 | Dade International Inc. | Tetrahydroxyquinone as an activator component for activated partial thromboplastin time test of blood coagulation | | US5583006 | May 4, 1995 | Dec 10, 1996 | Boehringer Mannheim Corporation | Stabilizing tetrazolium salts in a reagent | | US5702955 | Oct 6, 1995 | Dec 30, 1997 | Bayer Corporation | Ascorbate resistant detection of hydrogen peroxide | | US5837546 | Jun 7, 1996 | Nov 17, 1998 | Metrika, Inc. | Electronic assay device and method | | US5968746 | Nov 26, 1997 | Oct 19, 1999 | | Method and apparatus for preserving human saliva for testing | | US6120676 | Jun 4, 1999 | Sep 19, 2000 | Therasense, Inc. | Method of using a small volume in vitro analyte sensor | | US6143164 | Dec 16, 1998 | Nov 7, 2000 | E. Heller & Company | Small volume in vitro analyte sensor | | US6251260 | Aug 24, 1998 | Jun 26, 2001 | TheraSense, Inc. | Potentiometric sensors for analytic determination | | US6291178 | Aug 30, 1999 | Sep 18, 2001 | | Method and apparatus for preserving human saliva for testing | | US6299757 | Oct 6, 1999 | Oct 9, 2001 | TheraSense, Inc. | Small volume in vitro analyte sensor with diffusible or non-leachable redox mediator | | US6338790 | Apr 21, 1999 | Jan 15, 2002 | TheraSense, Inc. | Small volume in vitro analyte sensor with diffusible or non-leachable redox mediator | | US6461496 | Oct 27, 1999 | Oct 8, 2002 | TheraSense, Inc. | Small volume in vitro analyte sensor with diffusible or non-leachable redox mediator | | US6534300 | Aug 10, 2000 | Mar 18, 2003 | Genzyme Glycobiology Research Institute, Inc. | Methods for producing highly phosphorylated lysosomal hydrolases | | US6537785 | Aug 10, 2000 | Mar 25, 2003 | Genzyme Glycobiology Research Institute, Inc. | Methods of treating lysosomal storage diseases | | US6551494 | Apr 6, 2000 | Apr 22, 2003 | Therasense, Inc. | Small volume in vitro analyte sensor | | US6576101 | Oct 6, 1999 | Jun 10, 2003 | TheraSense, Inc. | Small volume in vitro analyte sensor | | US6591125 | Jun 27, 2000 | Jul 8, 2003 | TheraSense, Inc. | Small volume in vitro analyte sensor with diffusible or non-leachable redox mediator | | US6592745 | May 17, 2000 | Jul 15, 2003 | TheraSense, Inc. | Method of using a small volume in vitro analyte sensor with diffusible or non-leachable redox mediator | | US6616819 | Nov 4, 1999 | Sep 9, 2003 | TheraSense, Inc. | Small volume in vitro analyte sensor and methods | | US6618934 | Jun 15, 2000 | Sep 16, 2003 | TheraSense, Inc. | Method of manufacturing small volume in vitro analyte sensor | | US6654625 | Jun 16, 2000 | Nov 25, 2003 | TheraSense, Inc. | Mass transport limited in vivo analyte sensor | | US6656697 | Feb 25, 2000 | Dec 2, 2003 | Lifescan, Inc. | Diagnostics based on tetrazolium compounds | | US6670165 | Nov 9, 2001 | Dec 30, 2003 | Genzyme Glycobiology Research Institute, Inc. | Methods for producing highly phosphorylated lysosomal hydrolases | | US6749740 | Dec 28, 2001 | Jun 15, 2004 | TheraSense, Inc. | Small volume in vitro analyte sensor and methods | | US6800472 | Dec 21, 2001 | Oct 5, 2004 | Genzyme Glycobiology Research Institute, Inc. | Expression of lysosomal hydrolase in cells expressing pro-N-acetylglucosamine-1-phosphodiester | | US6828135 | Nov 29, 2002 | Dec 7, 2004 | Genzyme Glycobiology Research Institute, Inc. | Phosphodiester | | US6861242 | Jul 2, 2001 | Mar 1, 2005 | Genzyme Glycobiology Research Institute, Inc. | Methods for producing highly phosphorylated lysosomal hydrolases | | US6905856 | Dec 21, 2001 | Jun 14, 2005 | Genzyme Glycobiology Research Institute, Inc. | Soluble GlcNAc phosphotransferase | | US6942518 | Dec 28, 2001 | Sep 13, 2005 | TheraSense, Inc. | Small volume in vitro analyte sensor and methods | | US6975893 | Nov 25, 2003 | Dec 13, 2005 | TheraSense, Inc. | Mass transport limited in vivo analyte sensor | | US7005273 | May 14, 2002 | Feb 28, 2006 | TheraSense, Inc. | Method for the determination of glycated hemoglobin | | US7011954 | Sep 15, 2003 | Mar 14, 2006 | Lifescan, Inc. | Diagnostics based on tetrazolium compounds | | US7041468 | Mar 29, 2002 | May 9, 2006 | TheraSense, Inc. | Blood glucose tracking apparatus and methods | | US7058437 | Apr 17, 2003 | Jun 6, 2006 | TheraSense, Inc. | Methods of determining concentration of glucose | | US7067127 | Sep 9, 2003 | Jun 27, 2006 | Genzyme Glycobiology Research Institute Inc. | GIcNAc phosphotransferase of the lysosomal targeting pathway | | US7102011 | Dec 18, 2001 | Sep 5, 2006 | | Methods and compositions for the visualization of cellular organelles using tetrazolium salts | | US7135322 | Jul 29, 2004 | Nov 14, 2006 | Novazyme Pharmaceuticals, Inc. | Expression of lysosomal hydrolase in cells expressing pro-N-acetylglucosamine-1-phosphodiester α-N-acetyl glucosimanidase | | US7144709 | Nov 16, 2004 | Dec 5, 2006 | LifeScan, Inc. | Diagnostics based on tetrazolium compounds | | US7150995 | Jan 16, 2004 | Dec 19, 2006 | Metrika, Inc. | Methods and systems for point of care bodily fluid analysis | | US7225535 | Sep 12, 2003 | Jun 5, 2007 | Abbott Diabetes Care, Inc. | Method of manufacturing electrochemical sensors | | US7371366 | Aug 9, 2005 | May 13, 2008 | Genzyme Corporation | GlcNAc phosphotransferase of the lysosomal targeting pathway | | US7550069 | Sep 12, 2003 | Jun 23, 2009 | Abbott Diabetes Care Inc. | Small volume in vitro analyte sensor | | US7563350 | Sep 15, 2003 | Jul 21, 2009 | Abbott Diabetes Care Inc. | Small volume in vitro analyte sensor | | US7587287 | Apr 4, 2003 | Sep 8, 2009 | Abbott Diabetes Care Inc. | Method and system for transferring analyte test data | | US7620438 | Mar 31, 2006 | Nov 17, 2009 | Abbott Diabetes Care Inc. | Method and system for powering an electronic device | | US7635597 | Apr 19, 2004 | Dec 22, 2009 | Bayer HealthCare LLC | Dry reagent particle assay and device having multiple test zones and method therefor | | US7766829 | Nov 4, 2005 | Aug 3, 2010 | Abbott Diabetes Care Inc. | Method and system for providing basal profile modification in analyte monitoring and management systems | | US7799578 | May 29, 2007 | Sep 21, 2010 | Roche Diagnostics GmbH | Capillary active test element having an intermediate layer situated between the support and the covering | | US7811231 | Dec 26, 2003 | Oct 12, 2010 | Abbott Diabetes Care Inc. | Continuous glucose monitoring system and methods of use | | US7811689 | Jun 26, 2007 | Oct 12, 2010 | Abbott Diabetes Care Inc. | Biological fuel cell and methods | | US7860544 | Mar 7, 2007 | Dec 28, 2010 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use | | US7869853 | Aug 6, 2010 | Jan 11, 2011 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use | | US7885699 | Aug 6, 2010 | Feb 8, 2011 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use | | US7906009 | Jul 30, 2008 | Mar 15, 2011 | Abbott Diabetes Care Inc. | Small volume in vitro analyte sensor | | US7909984 | Feb 7, 2008 | Mar 22, 2011 | Abbott Diabetes Care Inc. | Small volume in vitro analyte sensor | | US7920907 | Jun 7, 2007 | Apr 5, 2011 | Abbott Diabetes Care Inc. | Analyte monitoring system and method | | US7928850 | May 8, 2008 | Apr 19, 2011 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods | | US7976778 | Jun 22, 2005 | Jul 12, 2011 | Abbott Diabetes Care Inc. | Blood glucose tracking apparatus | | US7988845 | Jan 28, 2008 | Aug 2, 2011 | Abbott Diabetes Care Inc. | Integrated lancing and measurement device and analyte measuring methods | | US7998624 | Sep 7, 2010 | Aug 16, 2011 | Abbott Diabetes Care Inc. | Biological fuel cell and methods | | US7998625 | Nov 11, 2010 | Aug 16, 2011 | Abbott Diabetes Care Inc. | Biological fuel cell and methods | | US8066639 | Jun 4, 2004 | Nov 29, 2011 | Abbott Diabetes Care Inc. | Glucose measuring device for use in personal area network | | US8066858 | Oct 31, 2007 | Nov 29, 2011 | Abbott Diabetes Care Inc. | Analyte sensor with insertion monitor, and methods | | US8067188 | Apr 16, 2010 | Nov 29, 2011 | N2ITIVE1 Innovations | Analyte detection | | US8083924 | Sep 29, 2009 | Dec 27, 2011 | Abbott Diabetes Care Inc. | Small volume in vitro analyte sensor and methods of making | | US8083928 | Sep 29, 2009 | Dec 27, 2011 | Abbott Diabetes Care Inc. | Small volume in vitro analyte sensor and methods of making | | US8083929 | Sep 29, 2009 | Dec 27, 2011 | Abbott Diabetes Care Inc. | Small volume in vitro sensor and methods of making | | US8087162 | Sep 29, 2009 | Jan 3, 2012 | Abbott Diabetes Care Inc. | Methods of making small volume in vitro analyte sensors | | US8091220 | Oct 31, 2007 | Jan 10, 2012 | Abbott Diabetes Care Inc. | Methods of making small volume in vitro analyte sensors | | US8103456 | Jan 29, 2009 | Jan 24, 2012 | Abbott Diabetes Care Inc. | Method and device for early signal attenuation detection using blood glucose measurements | | US8105476 | Jul 30, 2007 | Jan 31, 2012 | Abbott Diabetes Care Inc. | Integrated lancing and measurement device | | US8112240 | Apr 29, 2005 | Feb 7, 2012 | Abbott Diabetes Care Inc. | Method and apparatus for providing leak detection in data monitoring and management systems | | US8114270 | Feb 7, 2008 | Feb 14, 2012 | Abbott Diabetes Care Inc. | Small volume in vitro analyte sensor | | US8114271 | Sep 29, 2009 | Feb 14, 2012 | Abbott Diabetes Care Inc. | Small volume in vitro analyte sensor | | US8118992 | Sep 29, 2009 | Feb 21, 2012 | Abbott Diabetes Care Inc. | Small volume in vitro analyte sensor | | US8118993 | Sep 29, 2009 | Feb 21, 2012 | Abbott Diabetes Care Inc. | Small volume in vitro analyte sensor and methods of making | | US8123686 | Mar 1, 2007 | Feb 28, 2012 | Abbott Diabetes Care Inc. | Method and apparatus for providing rolling data in communication systems | | US8123929 | Sep 29, 2009 | Feb 28, 2012 | Abbott Diabetes Care Inc. | Small volume in vitro analyte sensor | | US8142642 | Jul 30, 2008 | Mar 27, 2012 | Abbott Diabetes Care Inc. | Small volume in vitro analyte sensor | | US8142643 | Sep 29, 2009 | Mar 27, 2012 | Abbott Diabetes Care Inc. | Small volume in vitro analyte sensor | | US8149117 | Aug 29, 2009 | Apr 3, 2012 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods | | US8153063 | Sep 29, 2009 | Apr 10, 2012 | Abbott Diabetes Care Inc. | Small volume in vitro analyte sensor and methods of making | | US8162829 | Mar 30, 2009 | Apr 24, 2012 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use | | US8163164 | Sep 29, 2009 | Apr 24, 2012 | Abbott Diabetes Care Inc. | Small volume in vitro analyte sensor and methods of making | | US8175673 | Nov 9, 2009 | May 8, 2012 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use | | US8177716 | Dec 21, 2009 | May 15, 2012 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use | | US8182670 | Sep 29, 2009 | May 22, 2012 | Abbott Diabetes Care Inc. | Small volume in vitro analyte sensor and methods of making | | US8182671 | Sep 29, 2009 | May 22, 2012 | Abbott Diabetes Care Inc. | Small volume in vitro analyte sensor and methods of making | | US8186044 | Apr 13, 2007 | May 29, 2012 | Abbott Diabetes Care Inc. | Method of manufacturing small volume in vitro analyte sensors | | US8187183 | Oct 11, 2010 | May 29, 2012 | Abbott Diabetes Care Inc. | Continuous glucose monitoring system and methods of use | | US8187895 | Sep 29, 2009 | May 29, 2012 | Abbott Diabetes Care Inc. | Small volume in vitro analyte sensor and methods of making | | US8192611 | Sep 29, 2009 | Jun 5, 2012 | Abbott Diabetes Care Inc. | Small volume in vitro analyte sensor and methods of making | | US8206563 | Dec 6, 2005 | Jun 26, 2012 | Abbott Diabetes Care Inc. | Device for the determination of glycated hemoglobin | | US8211363 | Sep 29, 2009 | Jul 3, 2012 | Abbott Diabetes Care Inc. | Small volume in vitro analyte sensor and methods of making | | US8221685 | Sep 29, 2009 | Jul 17, 2012 | Abbott Diabetes Care Inc. | Small volume in vitro sensor and methods of making | | US8224413 | Oct 10, 2008 | Jul 17, 2012 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use | | US8226555 | Mar 18, 2009 | Jul 24, 2012 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use | | US8226557 | Dec 28, 2009 | Jul 24, 2012 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use | | US8226558 | Sep 27, 2010 | Jul 24, 2012 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use | | US8226815 | Sep 29, 2009 | Jul 24, 2012 | Abbott Diabetes Care Inc. | Small volume in vitro sensor and methods of making | | US8226891 | Mar 31, 2006 | Jul 24, 2012 | Abbott Diabetes Care Inc. | Analyte monitoring devices and methods therefor | | US8231532 | Apr 30, 2007 | Jul 31, 2012 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use | | US8235896 | Dec 21, 2009 | Aug 7, 2012 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use | | US8236242 | Feb 12, 2010 | Aug 7, 2012 | Abbott Diabetes Care Inc. | Blood glucose tracking apparatus and methods | | US8241797 | Nov 11, 2010 | Aug 14, 2012 | Abbott Diabetes Care Inc. | Biological fuel cell and methods |
Claims1. A colorimetric assay system which is designed to measure the presence or concentration of a biochemical analyte in a sample by a color change which is indicative of the presence or concentration of the analyte, wherein the system comprises, - (a) an oxidase enzyme capable of oxidizing the analyte by removing electrons from the analyte without involving oxygen in the reaction, thereby yielding a reduced enzyme,
- (b) a non-chromogenic electron acceptor which is oxygen, having a half cell reduction potential greater than that of the reduced enzyme, wherein the electron acceptor is capable of accepting electrons from the reduced enzyme in a functionally irreversible manner, and
- (c) a chromogen which is capable of accepting electrons from the reduced enzyme and changing color in a visible range upon reduction, wherein the change of color is less than one equivalent of color per equivalent of analyte oxidized and is indicative of the presence or the concentration of the analyte to be determined.
2. The colorimetric assay system of claim 1 wherein the electron acceptor is capable of directly accepting the electrons from the reduced enzyme in a functionally irreversible manner. 3. The colorimetric assay system of claim 1 wherein the analyte is cholesterol and the enzyme is cholesterol oxidase. 4. The colorimetric assay system of claim 3 wherein the chromogen is Azure B. 5. A colorimetric assay system which is designed to measure the presence or concentration of a biochemical analyte by a color change which is determinative of the presence of concentration of the analyte, wherein the system comprises: - (a) an oxidase enzyme capable of electron transferase activity with the analyte and capable of oxidizing the analyte by removing electrons from the analyte without involving oxygen in the reaction, thereby yielding a reduced enzyme,
- (b) a chromogen which is capable of accepting electrons derived from the reduced enzyme and is capable of changing color in a visible range upon reduction, the color change of the reduced chromogen being detectable and determinative of the presence or concentration of the analyte to be determined, and
- (c) a non-chromogenic electron acceptor which is not oxygen having a half cell potential greater than the reduced enzyme, which electron acceptor is capable of accepting electrons derived from the reduced enzyme in a functionally irreversible manner, and advantageously competes over any oxygen present to oxidize the reduced enzyme, and
- (d) an electron transfer agent which promotes the transfer of electrons from the reduced enzyme to the electron acceptor, the chromogen, or both.
6. The colorimetric assay system of claim 5 wherein the electron transfer agent is selected from the group consisting of flavins, phenazines, phenothiazines, pheoxazines, indophenols, substituted 1,4-benzoquinones and indamins. 7. The colorimetric assay system of claim 6 wherein the electron transfer agent is a flavin selected from the group consisting of riboflavin, alloxazine and lumichrome. 8. The colorimetric assay system of claim 6 in which the electron transfer agent is a phenothiazine selected from the group consisting of phenothiazine radical cation, thionine, azure A, azure B, azure C, methylene blue, methylene green and toluidine blue. 9. The colorimetric assay system of claim 6 wherein the electron transfer agent is a phenazine selected from the group consisting of phenazine, phenazine methosulfate, phenazine ethosulfate, and safranine. 10. The colorimetric assay system of claim 6 in which the electron transfer agent is a phenothiazine selected from the group consisting of basic blue 3 and brilliant cresyl blue. 11. The colorimetric assay system of claim 6 in which the electron transfer agent is a substituted 1,4-benzoquinone selected from the group consisting of TFBQ, MMBQ, HMBQ, HMMBQ, DMBQ, DMMBQ and CCBQ. 12. The colorimetric assay system of claim 6 in which the electron transfer agent is an indamin selected from the group consisting of Bindschedler's green and phenylene blue. 13. The colorimetric assay system of claim 5 in which the enzyme is cholesterol oxidase and the analyte is cholesterol. 14. The colorimetric assay system of claim 7 in which the electron transfer agent is DCIP. 15. The colorimetric assay system of claim 14 in which the enzyme is choline oxidase and the analyte is choline. 16. The colorimetric assay system of claim 5 in which the electron acceptor competes with the chromogen for electrons from the enzyme, either retarding reduction of the chromogen and thereby causing the color change to be gradual, or preventing reduction of the chromogen until the non-reduced electron acceptor is depleted and an abrupt color change occurs, the intensity of the gradual color change being linearly proportional to the concentration of the analyte, the occurrence of the abrupt color change being determinative of the presence or absence of the analyte below or above a concentration to be determined. 17. The colorimetric assay system of claim 5 wherein the electron transfer agent is phenothiazine, the chromogen is INT and the electron acceptor is ferric chelate. 18. The colorimetric assay system of claim 5 wherein the electron transfer agent is PMS, the chromogen is MTT and the electron acceptor is ferricyanide. 19. The colorimetric assay system of claim 18 in which the enzyme is alcohol oxidase and the analyte is alcohol. 20. The colorimetric assay system of claim 5 wherein the analyte is cholesterol, the enzyme is cholesterol oxidase, the electron transfer agent is selected from the group consisting of phenothiazine radical, phenoxazine, PMS and a substituted 1,4-benzoquinone, the electron acceptor is selected from the group consisting of K.sub.2 IrCl.sub.6, ferric chelates, ferricyanide, and NaIO.sub.4 and the chromogen is a tetrazolium salt compatible with the electron acceptor, and wherein the assay system is analog to digital. 21. The colorimetric assay system of claim 20 wherein the substituted 1,4-benzoquinone electron transfer agent is selected from the group consisting of TFBQ, MMBQ, DMMBQ and CCBQ. 22. The colorimetric assay system of claim 5 wherein the analyte is cholesterol, the enzyme is cholesterol oxidase, the electron transfer agent is selected from the group consisting of phenothiazine radical cation, phenoxazine, phenazine methosulfate and a substituted 1,4-benzoquinone, the electron acceptor is tartrazine, and the chromogen is a tetrazolium salt compatible with the electron acceptor, and wherein the assay system is analog to analog. 23. The colorimetric assay system of claim 5 in which the oxidase is selected from the group consisting of an oxidase requiring a flavin coenzyme and an oxidase containing a pteridine coenzyme. 24. The colorimetric assay system of claim 5 wherein the oxidase contains a reversible oxidizable dithiol group at its active site. 25. The colorimetric assay system of claim 5 wherein the oxidase contains non-heme iron in its reactive center. 26. The colorimetric assay system of claim 5 wherein the electron transfer agent promotes the transfer of electrons to both the chromogen and the electron acceptor. 27. The colorimetric assay system of claim 5 wherein the reduced chromogen has a millimolar extinction coefficient in excess of 10. 28. The colorimetric assay system of claim 5 wherein the electron acceptor is capable of efficient direct interaction with the enzyme and the electron transfer agent promotes the transfer of electrons to the chromogen. 29. The colorimetric assay system of claim 5 wherein the chromogen is capable of efficient direct interaction with the enzyme and the electron transfer agent promotes the transfer of electrons to the electron acceptor. 30. The colorimetric assay system of claim 5 wherein the electron acceptor, the chromogen, or both the electron acceptor and the chromogen are capable of accepting electrons from the reduced enzyme and from electron transfer agent, wherein the electron transfer agent increases the rate of electron transfer, thereby reducing the amount of enzyme needed to achieve a desired rate. 31. The colorimetric assay system of claim 5 wherein the analyte is glucose, and the enzyme is glucose oxidase. 32. The colorimetric assay system of claim 5 wherein the electron transfer agent and the electron acceptor are a hybrid phenothiazine radical cation, and the chromogen is MTT. 33. The colorimetric assay system of claim 32 wherein the phenothiazine radical cation is prepared from phenothiazine and an electron acceptor oxidizing agent selected from the group consisting of K.sub.2 IrCl.sub.6, NaIO.sub.4, and ferric chelates. 34. The colorimetric assay system of claim 33 wherein the ferric chelate is selected from the group consisting of ferricyanide, ferric EDTA, ferric citrate, ferric oxalate, ferric acetylacetonate, ferric bipyridyl, nitroferricyanide and pentacyanoamino ferrate (III). 35. The colorimetric assay system of claim 5 wherein the assay system is analog to analog and wherein the color change is directly proportional to the concentration of analyte to be measured. 36. The colorimetric assay system of claim 35 wherein the electron acceptor is selected from the group consisting of tartrazine, TFBQ, 2,5,-dihydroxy-1,4-benzoquinone and 2-cyclohexyl-5-hydroxy-1,4-benzoquinone and the chromogen is a tetrazolium salt. 37. The colorimetric assay system of claim 35 wherein the biochemical analyte is bilirubin and the enzyme is bilirubin oxidase. 38. The colorimetric assay system of claim 35 wherein the analyte is cholesterol and the enzyme is cholesterol oxidase. 39. The colorimetric assay system of claim 5, further comprising the the biochemical analyte, the presence or concentration of which is to be measured. 40. The colorimetric assay system of claim 39 wherein the analyte is selected from the group consisting of ethanol, methanol, glucose, lactose, galactose, lactate, pyruvate, oxalate, ketones, albumin, triglycerides, cholesterol, bilirubin, hemoglobin, chlorine, oxalic acid, glycerol, lactic acid, pyruvic acid, ascorbic acid and uric acid, and the enzyme is an oxidase capable of oxidizing the analyte. 41. The colorimetric assay system of claim 5 wherein the oxidase is not capable of oxidizing the analyte as initially present, and wherein the assay system further comprises an enzyme or series of enzymes capable of converting the analyte to a product which can be oxidized by the oxidase. 42. The colorimetric assay system of claim 41 wherein the analyte is triglyceride, the enzyme capable of converting the analyte to a product which can be oxidized by the oxidase is a lipase, and the oxidase is glycerol oxidase. 43. The colorimetric assay system of claim 41 wherein the analyte is esterified cholesterol, the enzyme capable of converting the analyte to a product which can be oxidized by the oxidase is an enzyme with cholesterol esterase activity, and the oxidase is cholesterol oxidase. 44. The colorimetric assay system of claim 5 wherein the color change is a change from a colorless state to a colored stat in the visible range. 45. The colorimetric assay system of claim 5 wherein an additional electron transfer agent is added to promote the efficient transfer of electrons from any reduced chromogen to the electron acceptor. 46. The colorimetric assay system of claim 45 wherein the analyte is in a multi-phase composition and the components of the assay system partition differentially between the phases, and the additional electron transfer agent promotes the flow of electrons from reduced chromogen or electron transfer agent in one phase to the electron acceptor in another phase. 47. The colorimetric assay system of claim 46 wherein the multi-phase composition comprises micellar and ionic aqueous phases. 48. The colorimetric assay system of claim 47 wherein the micellar phase comprises lipoprotein particles and the aqueous phase comprises the aqueous component of blood. 49. The colorimetric assay system of claim 45 wherein the electron acceptor/electron transfer agent is a hybrid. 50. The colorimetric assay system of claim 45 wherein the electron transfer agent is phenazine methosulfate, the electron acceptor is ferricyanide, the chromogen is a tetrazolium salt and the electron transfer agent between the chromogen and the electron acceptor is phenoxazine. 51. A colorimetric assay system which is designed to measure the presence or concentration of an oxidase enzyme in a sample by a color change which is indicative of the presence or concentration of the oxidase, wherein the system comprises, - (a) a substrate which the oxidase is capable of oxidizing by removing electrons from the substrate without involving oxygen in the reaction, wherein the electrons are transferred to an electron acceptor, and wherein the electron acceptor is not oxygen,
- (b) a non-chromogenic electron acceptor which is not oxygen, having a half cell reduction potential greater than that of the reduced enzyme, wherein the electron acceptor is capable of accepting electrons from the reduced enzyme in a functionally irreversible manner,
- (c) a chromogen which is capable of accepting electrons from the reduced enzyme and changing color in a visible range upon reduction, wherein the change of color is less than one equivalent of color per equivalent of substrate oxidized and is indicative of the presence or the concentration of the oxidase to be determined, and
- (d) an electron transfer agent which promotes the transfer of electrons from the reduced enzyme to the electron acceptor, the chromogen, or both the electron acceptor and the chromogen.
52. A diagnostic colorimetric assay device which is designed to measure the concentration of a biochemical analyte in a sample by developing a color signal when the analyte is at or above a threshold concentration and by the absence of a color signal when the concentration of the analyte is below the threshold, wherein the device comprises: - (a) physical support means,
- (b) an oxidase enzyme capable of oxidizing the analyte by removing electrons from the analyte without involving oxygen in the reaction, thereby yielding a reduced enzyme,
- (c) a non-chromogenic electron acceptor which is oxygen, having a half cell reduction potential greater than that of the reduced enzyme, wherein the electron acceptor is capable of accepting electrons from the reduced enzyme in a functionally irreversible manner,
- (d) a chromogen which is capable of accepting electrons from the reduced enzyme and changing color in a visible range upon reduction, wherein the change of color is less than one equivalent of color per equivalent of analyte oxidized and is indicative of the concentration of the analyte to be determined, and
- (e) an electron transfer agent which promotes the transfer of electrons from the reduced enzyme to the electron acceptor, the chromogen, or both the electron acceptor and the chromogen.
53. The device of claim 52 wherein the physical support means is a multi-layer dry film or gel situated inside a controlled volume capillary. 54. The device of claim 52 which further comprises a sampling means. 55. The device of claim 54 wherein the sampling means is a lancet for sampling blood. 56. A method for measuring the presence or the concentration of a biochemical analyte in a sample by the development of a color change wherein the method comprises: - (a) contacting the sample with an assay system comprising
- (i) an oxidase enzyme capable of oxidizing the analyte by removing electrons from the analyte without involving oxygen in the reaction, thereby yielding a reduced enzyme,
- (ii) a non-chromogenic electron acceptor which is oxygen, having a half cell reduction potential greater than that of the reduced enzyme, wherein the electron acceptor is capable of accepting electrons from the reduced enzyme in a functionally irreversible manner,
- (iii) a chromogen which is capable of accepting electrons from the reduced enzyme and changing color in a visible range upon reduction, wherein the change of color is less than one equivalent of color per equivalent of analyte oxidized and is indicative of the concentration of the analyte to be determined, and
- (iv) an electron transfer agent which promotes the transfer of electrons from the reduced enzyme to the electron acceptor, the chromogen, or both the electron acceptor and the chromogen,
- (b) incubating to permit oxidation of the analyte, and
- (c) detecting a color change resulting from reduction of the chromogen, wherein a visible color change is indicative of the presence of the analyte or a concentration of the analyte above a predetermined threshold and wherein the absence of a visible color change is indicative of the absence of the analyte or a concentration of the analyte below a predetermined threshold.
57. A method for measuring the presence or the concentration of an oxidase enzyme in a sample by the development of a color change wherein the color change is indicative of the presence or concentration of the oxidase, wherein the method comprises: - (a) contacting the sample with an assay system comprising
- (i) a substrate which the oxidase is capable of oxidizing by removing electrons from the substrate without involving oxygen in the reaction, wherein the electrons are transferred to an electron acceptor, and wherein the electron acceptor is not oxygen,
- (ii) a non-chromogenic electron acceptor which is not oxygen, having a half cell reduction potential greater than that of the reduced enzyme, wherein the electron acceptor is capable of accepting electrons from the reduced enzyme in a functionally irreversible manner,
- (iii) a chromogen which is capable of accepting electrons from the reduced enzyme and changing color in a visible range upon reduction, wherein the change of color is less than one equivalent of color per equivalent of substrate oxidized and is indicative of the concentration of the substrate to be determined, and
- (iv) an electron transfer agent which promotes the transfer of electrons from the reduced enzyme to the electron acceptor, the chromogen, or both the electron acceptor and the chromogen,
- (b) incubating to permit the oxidation of the substrate, and
- (c) detecting a color change resulting from reduction of the chromogen, wherein a visible color change is indicative of the presence of the oxidase or a concentration of the oxidase above a predetermined threshold and wherein the absence of a visible color change is indicative of the absence of the oxidase or a concentration of the oxidase below a predetermined threshold.
58. The colorimetric assay system of claim 39, further comprising a reactant which reacts with the analyte to convert the analyte to a product in situ, and an oxidase capable of oxidizing the product. 59. The colorimetric assay system of claim 49 wherein the electron acceptor/electron transfer agent hybrid is phenothiazine radical cation, the electron transfer agent between the enzyme and the chromogen is DMMBQ, and the electron transfer agent between the chromogen and the electron acceptor is TFBQ. 60. A colorimetric assay system which is designed to measure the presence or concentration of a biochemical analyte in a sample by a color change which is determinative of the presence or concentration of the analyte, which system comprises: - (a) a heme- or copper-containing protein capable of oxidizing the analyte by removing electrons from the analyte without involving oxygen in the reaction thereby yielding a reduced protein,
- (b) a chromogen which is capable of accepting electrons from the reduced protein and is capable of changing color in a visible range upon reduction, the change of the reduced chromogen being detectable and determinative of the presence or concentration of the analyte to be determined, and
- (c) a non-chromogenic electron acceptor which is not oxygen, having a half cell potential greater than the reduced enzyme, wherein the electron acceptor is capable of accepting electrons from the reduced enzyme in a functionally irreversible manner, and
- (d) an electron transfer agent which promotes the transfer of electrons from the reduced enzyme to the electron acceptor, the chromogen, or both.
61. The colorimetric assay system of claim 60, wherein the heme- or copper-containing protein is selected from the group consisting of serum monoamine oxidase, liver dopamine hydroxylase, hemocyanin, laccase, uricase, phenolase, transsulferase, cerebrocuprein, erythrocyprein, hepatocuprein, plastocyanin, dopamine-2-hydroxylase, liver aryl-4-hydroxylase, liver naphthalene hydroxylase, alkoxyaryl hydroxylase and fatty acid desaturase. |